A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously in subjects with active psoriatic arthritis.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously in subjects with active psoriatic arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Golimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-REVEAL
  • Sponsors Centocor
  • Most Recent Events

    • 01 Nov 2016 Results of 5-year safety data from five trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-REVEAL, GO-RAISE) published in The Journal of Rheumatology.
    • 30 Oct 2013 Pooled 120-day safety results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 30 Oct 2013 Five-year results for Minimal Disease Activity rate presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top